Results 151 to 160 of about 205,750 (304)

Cigarette Smoke Exposure Attenuates T2R‐Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma

Head &Neck, EarlyView.
ABSTRACT Background Tobacco use is associated with worse outcomes in head and neck squamous cell carcinoma (HNSCC). Bitter taste receptor (T2R) activation induces apoptosis via calcium‐dependent signaling, and higher T2R expression correlates with increased survival in HNSCC.
Kyle Polen, Sarah Sywanycz, Gavin Turner, Brianna L. Hill, Lily Huang, Zoey A. Miller, Casey Hanna, Lovely Raghav, Devraj Basu, Robert J. Lee, Ryan M. Carey   +10 more
wiley   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

The impact of time‐to‐recurrence on post‐recurrence mortality in stage I–III colorectal cancer: A nationwide Danish cohort study

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) recurrence is a significant threat to survival despite surgery with curative intent. The characteristics of CRC recurrence, however, remain poorly understood, challenging postoperative surveillance. This study investigated post‐recurrence mortality and associations between time‐to‐recurrence and mortality among stage
Jesper Nors, Kåre Andersson Gotschalck, Rune Erichsen, Claus Lindbjerg Andersen   +3 more
wiley   +1 more source

Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma

International Journal of Cancer, EarlyView.
What's New? Esophageal adenocarcinoma (EAC) is an aggressive cancer with poor survival and variable response to perioperative chemotherapy. Although histopathological features correlate with outcomes, the relationship specifically between adherens junction (AJ) protein expression and treatment response in EAC remains uncertain.
Bastian Grothey, Heike Löser, Tillmann Bedau, Wolfgang Schröder, Christiane J. Bruns, Thomas Zander, Max Krämer, Reinhard Büttner, Alexander Quaas   +8 more
wiley   +1 more source

A population‑based propensity score matching analysis of neoadjuvant compared to adjuvant chemotherapy in luminal breast cancer

Scientific Reports
This study evaluated the long-term prognosis of patients with luminal (HR+/HER2−) breast cancer who underwent either neoadjuvant or adjuvant chemotherapy.
Chenhui Zheng, Danni Zheng, Yuzhu Zhang, Renzhi Lin, Zhibao Zheng   +4 more
doaj   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source

Effect of Interval Between Neoadjuvant Immunochemotherapy and Radical Resection of Non‐Small Cell Lung Cancer: A Multicenter, Retrospective Cohort Study

International Journal of Cancer, EarlyView.
The optimal timing of surgery after neoadjuvant immunochemotherapy (NICT) for locally advanced non‐small cell lung cancer (NSCLC) remains unclear. In this retrospective investigation, the impact of time interval on outcome was assessed among NSCLC patients who completed NICT before undergoing radical resection.
Jiayi Wang, Pingping Song, Yong Ge, Haitang Yang, Shuyuan Li, Ran Ma, Tianyue Ma, Shoujie Feng, Cheng Zhang, Teng Sun, Feng Yao, Jun Yi, Hao Zhang   +12 more
wiley   +1 more source

The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer

International Journal of Cancer, EarlyView.
Neoadjuvant endocrine therapy (NET) can help prevent metastases and improve survival in patients with hormone receptor‐positive (HR+) breast cancer. Identifying which HR+ patients will benefit from NET, however, remains challenging. Here, in a patient cohort in the Netherlands, the authors evaluated tumor‐stroma ratio (TSR) and magnetic resonance ...
Layla Andour, Sophie C. Hagenaars, Anne Florine de Groot, Elly M. M. Krol‐Warmerdam, Judith R. Kroep, Hans Marten Hazelbag, Gerrit‐Jan Liefers, Marieke E. Straver, Wilma E. Mesker   +8 more
wiley   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

International Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn   +19 more
wiley   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source